View all the latest information in
, arranged by trials and clinical studies. Listed below are recently added trial updates.
REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?
An interview from the 25th Congress of the EHA with Robert Zeiser, Medical Center – University of Freiburg,...
Subgroup analysis of ruxolitinib in patients with steroid-refractory acute GvHD – update from EHA 2020
A follow-up analysis of the REACH2 study, which examined responses in different subgroups of...
Treatment of SR-GvHD and subsequent trial updates at EHA 2020
This year at EHA2020, we will be providing coverage of the oral presentations that provide updates on the trials focusing on novel...
Editorial theme | Novel targets for the treatment of GvHD
This month’s educational theme on the GvHD Hub is focusing on novel targets in the treatment of chronic graft-versus-host disease (GvHD). GvHD...
Comparison of ruxolitinib with other therapies for steroid-refractory acute GvHD
A phase III study REACH2 comparing the efficacy and safety of ruxolitinib with nine commonly used therapies in patients...
TCT Meeting 2019 | Results from the REACH1 trial: ruxolitinib plus corticosteroids for the treatment of steroid-refractory acute graft-versus-host disease
The REACH1 study is a single-cohort, pivotal...
FDA grants priority review of remestemcel-L for certain children with acute GvHD
On the 1st of April, the U.S. FDA accepted a Biologics License Application for remestemcel-L for the treatment of...
Prospective study investigating a mesenchymal stem cells infusion, remestemcel-L, in pediatric patients with steroid-refractory acute GvHD
A phase III study (NCT02336230) designed to further evaluate...
BMT CTN 1101
BMT CTN 1203
BMT CTN 1501